8AFC

CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 12

8AFC の概要

• エントリーDOI: 10.2210/pdb8afc/pdb
• 関連するPDBエントリー: 7U90 8AFB
• 分子名称: GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (6 entities in total)
• 機能のキーワード: kras, gtpase, g12c, complex, inhibitor, oncoprotein
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 39816.65

構造登録者

Boettcher, J.,Kessler, D. (登録日: 2022-07-16, 公開日: 2022-11-09, 最終更新日: 2024-10-23)

主引用文献

Broker, J.,Waterson, A.G.,Smethurst, C.,Kessler, D.,Bottcher, J.,Mayer, M.,Gmaschitz, G.,Phan, J.,Little, A.,Abbott, J.R.,Sun, Q.,Gmachl, M.,Rudolph, D.,Arnhof, H.,Rumpel, K.,Savarese, F.,Gerstberger, T.,Mischerikow, N.,Treu, M.,Herdeis, L.,Wunberg, T.,Gollner, A.,Weinstabl, H.,Mantoulidis, A.,Kramer, O.,McConnell, D.B.,W Fesik, S.
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor.
J.Med.Chem., 65:14614-14629, 2022

PubMed Abstract: Activating mutations in KRAS are the most frequent oncogenic alterations in cancer. The oncogenic hotspot position 12, located at the lip of the switch II pocket, offers a covalent attachment point for KRAS inhibitors. To date, KRAS inhibitors have been discovered by first covalently binding to the cysteine at position 12 and then optimizing pocket binding. We report on the discovery of the in vivo active KRAS inhibitor BI-0474 using a different approach, in which small molecules that bind reversibly to the switch II pocket were identified and then optimized for non-covalent binding using structure-based design. Finally, the Michael acceptor containing warhead was attached. Our approach offers not only an alternative approach to discovering KRAS inhibitors but also provides a starting point for the discovery of inhibitors against other oncogenic KRAS mutants.

PubMed: 36300829
DOI: 10.1021/acs.jmedchem.2c01120

実験手法

X-RAY DIFFRACTION (2.41 Å)